Juncell Therapeutics Announces Data on Feeder-free IL-2-Independent TIL Manufacturing Process at ASGCT Annual Meeting 2025
SHANGHAI, April 28, 2025 /PRNewswire/ -- Shanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics), a clinical-stage biotech specializing in developing innovative IL-2-independent Tumor-Infiltrating Lymphocyte (TIL) therapies for cancer, today announced it will present preclinical data on a feeder-free manufacturing process for IL-2-independent TIL expansion at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place May 13-15, 2025, in New Orleans, LA.
The study highlights Juncell Therapeutics' breakthroughs in TIL process development, demonstrating that its proprietary feeder-free system can generate robust, functional TILs from both "hot" and "cold" tumor tissues without relying on high-concentration interleukin-2 (IL-2). These TILs exhibited significant anti-tumor activity in syngeneic patient-derived organoid (PDO) and patient-derived xenograft (PDX) models. By eliminating IL-2 dependence and removing the need for feeder cells, the technology paves the way for safer TIL treatment regimens and reduces manufacturing costs.
Presentation Details:
Title: Development of A Feeder-Free Process for IL-2-Independent TIL Expansion
Poster Number: AMA362
Session: Thursday Poster Reception
Date and Time: May 15, 2025, 5:30 PM-7:00 PM
Location: Poster Hall Hall I2
About Juncell Therapeutics
Juncell Therapeutics is a biotech dedicated to developing high-quality, accessible IL-2 independent TIL therapies for the treatment of solid tumors. Juncell Therapeutics has established its proprietary DeepTIL® cell expansion and NovaGMP® gene modification technology platforms, which are designed to address the key challenges of conventional TIL therapies, making TILs "robust, competent, affordable, and accessible." Two clinical-stage TIL therapies have demonstrated promising safety and efficacy in the treatment of ten types of heavily pretreated advanced solid tumors, including lung cancer, triple-negative breast cancer, pancreatic cancer, high-grade glioma, ovarian cancer, endometrial cancer, cervical cancer, head and neck cancer, bile duct cancer and melanoma.
For more information, please visit:
https://www.linkedin.com/company/juncell-therapeutics
Juncell Contact:
View original content:https://www.prnewswire.com/news-releases/juncell-therapeutics-announces-data-on-feeder-free-il-2-independent-til-manufacturing-process-at-asgct-annual-meeting-2025-302439607.html
SOURCE Shanghai Juncell Therapeutics Co., Ltd.
